Biopsy News and Research

RSS

Biopsy is the removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.

FDA provides PMA approval for Spectrascience's WavSTAT technology enhancements

SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that its application for premarket approval (PMA) relating to key enhancements of its WavSTAT platform technology has been approved by the Food and Drug Administration. The Company can now begin commercial distribution of the enhanced WavSTAT technology.

17 Sep 2009

Educational events for physicians who diagnose and treat prostate cancer

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a series of educational events designed for radiologists, urologists, oncologists, radiation oncologists, surgeons, technologists and other referring physicians who diagnose and treat patients with prostate cancer.

17 Sep 2009

Bioheart's MARVEL Phase II/III clinical trial successful

Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University, presented the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session.

17 Sep 2009

Diagnocure reports third-quarter fiscal 2009 results

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced revenue of $396,468 and a net loss of $4,034,364 or $0.09 per share for the third quarter ending July 31, 2009.

17 Sep 2009

Cryosurgery: Primary treatment option for prostate cancer

After years of innovation and intensive research, a team of Binghamton University (BU) researchers working with Cell Preservation Services, Inc., Owego, NY has broken extraordinary new ground in the recognition of cryosurgery as a primary treatment option for prostate cancer.

16 Sep 2009

Patients with celiac disease face increased risk of mortality

New research indicates that patients with lesser degrees of celiac disease-related symptoms, such as intestinal inflammation or latent celiac disease, have a modestly increased risk of death, according to a study in the September 16 issue of JAMA.

16 Sep 2009

Mobetron portable radiation therapy system for breast cancer treatment

One minute of radiation in the operating room (OR) could save the lives of thousands of women being treated for breast cancer in the US today. According to a growing body of research, a 60-second course of radiation therapy delivered during surgery dramatically improves results. But, until recently, logistical and administrative difficulties prevented most patients from receiving this crucial treatment until weeks after their procedures.

16 Sep 2009

Third-quarter fiscal 2009 results announced by DiagnoCure

15 Sep 2009

Breast Preservation Foundation stresses on the importance public health education programs

Amidst the ongoing health-policy debate, Los Angeles surgeon Joel Aronowitz, M.D., founder of the Breast Preservation Foundation, furthered his organization’s health education and quality of care mission by meeting Washington policymakers to discuss how health care reform can help breast cancer patients be informed of all their treatment choices and have access to more advanced techniques like skin-sparing mastectomy.

15 Sep 2009

Quest Diagnostics' OVA1 ovarian cancer test cleared by the FDA

The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy.

From Quest Diagnostics 14 Sep 2009

Test for detecting ovarian cancer

The U.S. Food and Drug Administration today cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom.

14 Sep 2009

Abell Foundation plays major role in BioMarker's $1.7M private placement funding

BioMarker Strategies announced today that it has raised $1.7 million in a private placement funding round that occurred in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. BioMarker Strategies is developing the patent-pending, SnapPath™ testing system to enable oncologists to determine the most effective drug treatment for their cancer patients.

11 Sep 2009

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

10 Sep 2009

New web-based tool guide practices to become patient-centered medical home

The American College of Physicians (ACP) is offering a new, web-based tool to help guide practices through the process of becoming a patient-centered medical home (PCMH).

9 Sep 2009

Identifying a specific molecular signature can help customize cancer treatment

A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.

7 Sep 2009

Researchers study tumor diversity to improve breast cancer treatment

One person's breast cancer is not the same as another person's, because the gene mutations differ in each tumor. That makes it difficult to match the best therapy with the individual patient.

5 Sep 2009

Oncotype DX multigene expression test for breast cancer patients

In an effort to provide breast cancer patients with prompt, critical information about treatment options for use at their first visit with the medical oncologist, a number of leading U.S. surgeons request Genomic Health's Oncotype DX molecular test at the time of surgery or biopsy.

4 Sep 2009

Study reports a potential new investigational therapy for skin cancer

A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients.

3 Sep 2009

New therapy for advanced and metastatic basal cell skin cancer

3 Sep 2009

Dr. Samadi of the Mount Sinai Medical Center stresses on prostate cancer awareness

September signifies the start of fall, back to school and back to homework. September is also National Prostate Cancer Awareness Month. The awareness month was proclaimed by President Bush in 2003, and bolstered later that year by former New York mayor Rudy Giuliani, a prostate cancer survivor, who became the spokesman for the National Prostate Cancer Coalition.

2 Sep 2009